Trial Profile

A clinical program in renal space targeting an orphan indication

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 11 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Setanaxib (Primary)
Indications Kidney disorders
Focus Therapeutic Use

Most Recent Events

11 Oct 2023 New trial record
05 Oct 2023 According to a Calliditas Therapeutics AB media release, COMP has issued a positive opinion for orphan drug designation for setanaxib and company is excited to start this clinical program in the renal space targeting an orphan indication.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com